Company Analysis Evolent Health
1. Summary
Advantages
- The stock's return over the last year (0.7092%) is higher than the sector average (-26.12%).
- The company's current efficiency (ROE=-10.59%) is higher than the sector average (ROE=-80.94%)
Disadvantages
- Price (24.14 $) is higher than fair price (19.61 $)
- Dividends (0%) are below the sector average (1.24%).
- Current debt level 22.64% has increased over 5 years from 12.9%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Evolent Health | Healthcare | Index | |
|---|---|---|---|
| 7 days | 102% | 2.3% | 0.8% |
| 90 days | -23.7% | -36.1% | 6.8% |
| 1 year | 0.7% | -26.1% | 32.2% |
EVH vs Sector: Evolent Health has outperformed the "Healthcare" sector by 26.83% over the past year.
EVH vs Market: Evolent Health has significantly underperformed the market by -31.5% over the past year.
Stable price: EVH is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EVH with weekly volatility of 0.0136% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (24.14 $) is higher than the fair price (19.61 $).
Price is higher than fair: The current price (24.14 $) is 18.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (47.41).
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.34) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (3.34) is lower than that of the market as a whole (22.54).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.82) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (1.82) is lower than that of the market as a whole (15.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (86.69) is higher than that of the sector as a whole (17.44).
EV/Ebitda vs Market: The company's EV/Ebitda (86.69) is higher than that of the market as a whole (22.02).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -12.6% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-12.6%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (-10.59%) is higher than that of the sector as a whole (-80.94%).
ROE vs Market: The company's ROE (-10.59%) is lower than that of the market as a whole (16.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-4.22%) is lower than that of the sector as a whole (6.66%).
ROA vs Market: The company's ROA (-4.22%) is lower than that of the market as a whole (6.57%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-2.2%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (-2.2%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.24%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 07.03.2023 | WILLIAMS FRANK J Director |
Sale | 34.62 | 4 026 690 | 116 311 |
| 07.03.2023 | Blackley Seth Chief Executive Officer |
Sale | 34.62 | 3 290 800 | 95 055 |
| 06.03.2023 | WILLIAMS FRANK J Director |
Sale | 34.42 | 3 110 050 | 90 356 |
| 06.03.2023 | Blackley Seth Chief Executive Officer |
Sale | 34.42 | 2 544 600 | 73 928 |
| 03.03.2023 | WILLIAMS FRANK J Director |
Purchase | 34.42 | 13 768 000 | 400 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
